Effect of Urantide on the expression of ERK1/2 and P38 in the spleen of atherosclerotic rats

doi:10.13418/j.issn.1001-165x.2022.4.10

PDF(24515 KB)

Chinese Journal of Clinical Anatomy ›› 2022, Vol. 40 ›› Issue (4) : 425-431. DOI: 10.13418/j.issn.1001-165x.2022.4.10

Effect of Urantide on the expression of ERK1/2 and P38 in the spleen of atherosclerotic rats

Xu Yuhang¹, Li Ying¹, Xie Yunpeng², Wang Tu¹, Cui Haipeng¹, Zhao Juan¹*

Author information +

History +

Abstract

Objective To observe the effect of Urantide on the expression of ERK1/2 and P38 in MAPK signaling pathway in spleen of atherosclerotic rats, and to explore the effect and mechanism of Urantide on ERK1/2 and P38 MAPK signaling pathway in spleen. Methods A total of 180 wistar rats were randomly divided into a normal group, an AS group, a Simvastatin group, a Urantide 3 days, 7 days and 14 days group. The thoracic aorta and spleen of rats were observed by HE staining. Immunofluorescence, Western blotting were used to detect the expression of ERK1/2 and P38 in the spleen of rats. Results Compared with control group, the HE staining of AS group showed typical AS pathological changes in thoracic aorta, and hyaline degeneration in the central artery of spleen, the positive expression of p-ERK1/2 and p-P38 protein in the spleen of rats significantly increased (P<0.05). Compared with AS group, the hyaline degeneration in spleen significantly reduced in Urantide groups and Simvastatin group, the positive expression of p-ERK1/2 and p-P38 protein in spleen significantly decreased, especially in the Urantide 14 days group (P<0.05). Conclusions Urantide can improve the degree of pathological changes in spleen of AS rats by inhibiting the expression of ERK1/2 and P38.

Key words

Atherosclerosis; / / Spleen; / / Urotensin Ⅱ; / / Urantide; / / MAPK; / / ERK1/2; / / P38

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Xu Yuhang, Li Ying, Xie Yunpeng, Wang Tu, Cui Haipeng, Zhao Juan. Effect of Urantide on the expression of ERK1/2 and P38 in the spleen of atherosclerotic rats[J]. Chinese Journal of Clinical Anatomy. 2022, 40(4): 425-431 https://doi.org/10.13418/j.issn.1001-165x.2022.4.10

References

[1] Winkels H, Ehinger E, Vassallo M, et al. Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry[J]. Circ Res, 2018, 122(12): 1675-1688. DOI: 10.1161/CIRCRESAHA.117.312513.
[2] Watanabe T, Sato K, Itoh F, et al. Emerging roles for vasoactive peptides in diagnostic and therapeutic strategies against atherosclerotic cardiovascular diseases[J]. Curr Protein Pept Sci, 2013, 14(6): 472-480. DOI: 10.2174/13892037113149990064.
[3] Reustle A, Torzewski M. Role of p38 MAPK in atherosclerosis and aortic valve sclerosis[J]. Int J Mol Sci, 2018, 19(12): 3761. DOI: 10.3390/ijms19123761.
[4] Mizumoto Y, Kyo S, Mori N, et al. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis[J].Cancer Sci, 2007, 98(5): 652-658. DOI: 10.1111/j.1349-7006.2007.00445.x.
[5] 崔海鹏, 刘凯, 李颖, 等. Urantide对动脉粥样硬化大鼠肝细胞外调节蛋白激酶1/2的作用及机制[J]. 解剖学杂志, 2019, 42(3): 235-239, 282. DOI: 10.3969/j.issn.1001-1633.2019.03.004.
[6] 孙晓旭, 王途, 许倩, 等. Urantide降低动脉粥样硬化大鼠胸主动脉中p38 MAPK表达[J]. 基础医学与临床, 2019, 39(9): 1283-1288. DOI: 10.3969/j.issn.1001-6325.2019.09.013.
[7] Pereira-Castro J, Brás-Silva C, Fontes-Sousa AP. Novel insights into the role of urotensin II in cardiovascular disease[J]. Drug Discov Today, 2019, 24(11): 2170-2180. DOI: 10.1016/j.drudis.2019.08.005.
[8] Suguro T, Watanabe T, Ban Y, et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension[J]. Am J Hypertens, 2007, 20(2): 211-217. DOI: 10.1016/j.amjhyper. 2006. 08.001.
[9] Zhao J, Zhang SF, Shi Y, et al. Effects of urotensin II and its specific receptor antagonist urantide on rat vascular smooth muscle cells[J]. Bosn J Basic Med Sci,2013, 13(2): 78-83. DOI: 10.17305/bjbms. 2013.2369.
[10] Zhao J, Miao GX, Wang T, et al. Urantide attenuates myocardial damage in atherosclerotic rats by regulating the MAPK signalling pathway[J]. Life Sci, 2020, 262(11): 118551. DOI: 10.1016/j.lfs. 2020. 118551.
[11] 张延辉, 郭晓辰, 张军平, 等. 脾调节动脉粥样硬化的相关机制研究[J]. 中国免疫学杂志，2017, 33(9): 1412-1414. DOI: 10.3969/j.issn. 1000- 484X.2017.09.029.
[12] Wang YH， Huang ZY，Lu HX，et al. Apolipoprotein E-knockout mice show increased titers of serum anti-nuclear and anti-dsDNA antibodies[J]. Biochem Biophys Res Commun, 2012, 423(4): 805-812. DOI: 10.1016/j.bbrc.2012.06.044.
[13] Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice[J]. Nat Biotechnol, 2011, 29(11): 1005-1010. DOI: 10.1038/nbt.1989.
[14] Grasset EK, Duhlin A, Agardh HE, et al. Sterile inflammation in the spleen during atherosclerosis provides oxidation-specific epitopes that induce a protective B-cell response[J]. Proc Natl Acad Sci U S A, 2015, 112(16): E2030-E2038. DOI: 10.1073/pnas.1421227112.
[15] Lucas AR, Korol R, Pepine CJ. Inflammation in atherosclerosis: some thoughts about acute coronary syndromes[J]. Circulation, 2006, 113(17): e728-e732. DOI: 10.1161/CIRCULATIONAHA.105.601492.
[16]Viola J, Soehnlein O. Atherosclerosis-a matter of unresolved inflammation[J]. Semin Immunol, 2015, 27(3): 184-193. DOI: 10.1016/j.smim.2015.03.013.
[17]Potteaux S, Ait-Oufella H, Mallat Z. Role of splenic monocytes in atherosclerosis[J]. Curr Opin Lipidol, 2015, 26(5): 457-463. DOI: 10.1097/MOL.0000000000000223.
[18]Chistiakov DA, Grechko AV, Myasoedova VA, et al. The role of monocytosis and neutrophilia in atherosclerosis[J]. J Cell Mol Med, 2018, 22(3): 1366-1382. DOI: 10.1111/jcmm.13462.
[19]Robbins CS, Chudnovskiy A, Rauch PJ, et al. Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions[J]. Circulation, 2012, 125(2): 364-374. DOI: 10.1161/CIRCULATIONAHA.111.061986.
[20] Potteaux S, Gautier EL, Hutchison SB, et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression[J]. J Clin Invest, 2011, 121(5): 2025-2036. DOI: 10.1172/JCI43802.
[21] 赵依帆, 潘思京, 高真真, 等. 动脉粥样硬化的炎症信号通路研究进展[J]. 中华老年心脑血管病杂志, 2014, 16(12): 1332-1334. DOI: 10.3969/j.issn.1009-0126.2014.12.030.
[22] 徐瑞, 黄鹏, 张祎冰, 等. p38MAPK在动脉粥样硬化机制中的研究进展[J]. 中国老年学杂志, 2019, 39(17): 4365-4368. DOI: 10.3969/j.issn.1005-9202.2019.17.079.
[23] 杨翼鹰, 陈伟燕, 孙秀亭, 等. 麝香保心丸通过抑制p38 MAPK和NF-κB信号传导通路表达对抗高糖诱导的心肌细胞损伤[J]. 中国临床解剖学杂志, 2016, 34(5): 517-522, 527. DOI: 10.13418/j.issn.1001-165x. 2016.05.009.
[24] Sun LF, An DQ, Niyazi GL, et al. Effects of Tianxiangdan Granule treatment on atherosclerosis via NF‑κB and p38 MAPK signaling pathways[J]. Mol Med Rep, 2018, 17(1): 1642-1650. DOI: 10.3892/mmr.2017.8067.
[25] Cheng M, Yang LG, Fan M, et al. Proatherogenic stimuli induce HuR in atherosclerosis through MAPK/ErK pathway[J]. Am J Transl Res, 2019, 11(4): 2317-2327. PMID: 31105838.
[26] Yang Y, Kim SC, Yu T, et al. Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses[J]. Mediators Inflamm, 2014, 2014: 352371. DOI: 10.1155/2014/352371.
[27] McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance[J]. Biochim Biophys Acta, 2007, 1773(8): 1263-1284. DOI: 10.1016/j.bbamcr.2006.10.001.
[28] Emtiazy M, Choopani R, Khodadoost M, et al. Atheroprotector role of the spleen based on the teaching of Avicenna (Ibn Sina)[J]. Int J Cardiol, 2013, 167(1): 26-28. DOI: 10.1016/j.ijcard.2012.06.020.
[29] Akan AA, Sengül N, Simşek S, et al. The effects of splenectomy and splenic autotransplantation on plasma lipid levels[J]. J Invest Surg, 2008, 21(6): 369-372. DOI: 10.1080/08941930802438898.
[30] Svistunov AA, Tarasov VV, Shakhmardanova SA, et al. Urotensin II: molecular mechanisms of biological activity[J]. Curr Protein Pept Sci, 2018, 19(9): 924-934. DOI: 10.2174/1389203718666170829162335.
[31] Cui HP, Lin YX, Xie LD, et al. Urantide decreases hepatic steatosis in rats with experimental atherosclerosis via the MAPK/Erk/JNK pathway[J]. Mol Med Rep, 2021, 23(4): 284. DOI: 10.3892/mmr.2021.11923.
[32] 李英, 谢利德, 王途, 等. 多肽类化合物Urantide对动脉粥样硬化大鼠心脏组织中骨桥蛋白和α平滑肌肌动蛋白表达的影响[J]. 解剖学报,2021, 52(3): 446-452. DOI: 10.16098/j.issn.0529-1356. 2021. 03. 018.
[33] Wang T, Xie LD, Bi HD, et al. Urantide alleviates the symptoms of atherosclerotic rats in vivo and in vitro models through the JAK2/STAT3 signaling pathway[J]. Eur J Pharmacol, 2021, 902: 174037. DOI: 10.1016/j.ejphar.2021.174037.
[34]Wang T, Xie YQ, Miao GX, et al. Urotensin receptor antagonist urantide improves atherosclerosis-related kidney injury by inhibiting JAK2/STAT3 signaling pathway in rats[J]. Life Sci, 2020, 247: 11742. DOI: 10.1016/j.lfs.2020.117421.